Boston Scientific (BSX) Reports In-Line Q3 EPS; Modestly Lifts Outlook

October 26, 2016 6:33 AM EDT
Get Alerts BSX Hot Sheet
Trade BSX Now!
Join SI Premium – FREE

Get daily under-the-radar research with's Stealth Growth Insider Get your 2-Wk Free Trial here.

Boston Scientific (NYSE: BSX) reported Q3 EPS of $0.27, in-line with the analyst estimate of $0.27. Revenue for the quarter came in at $2.11 billion versus the consensus estimate of $2.07 billion.


Boston Scientific sees Q4 2016 EPS of $0.27-$0.29, versus the consensus of $0.27. Boston Scientific sees Q4 2016 revenue of $2.14-2.19 billion, versus the consensus of $2.15 billion.

Boston Scientific sees FY2016 EPS of $1.09-$1.11, versus prior guidance of $1.07-$1.00 and the consensus of $1.10. Boston Scientific sees FY2016 revenue of $8.335-8.385 billion, versus prior guidance of $8.27-8.37 billion and the consensus of $8.31 billion.

For earnings history and earnings-related data on Boston Scientific (BSX) click here.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Earnings, Guidance

Related Entities


Add Your Comment